Lawstreet Journal

Dr Reddy's Inks $61 Million Deal To Acquire Cidmus Brand In India From Novartis

Lawstreet Journal 5 Apr 2022 3:14am

Image courtesy: Lawstreet Journal Business Dr Reddy's Inks $61 Million Deal To Acquire Cidmus Brand In India From Novartis

Dr. Reddy's Laboratories announced on Friday that it has struck a deal with Novartis AG to purchase the Cidmus cardiovascular medication brand in India for $61 million (about Rs 463 crore). Dr Reddy's will be assigned and transferred the Cidmus trademark in India from Novartis AG for a fee of $61 million, according to a regulatory filing by the Hyderabad-based pharmaceutical company.

The Cidmus brand will be assigned to a pharmaceutical composition that contains a combination of Valsartan and Sacubitril (now patented by Novartis) and is intended for heart failure patients with a reduced ejection fraction, according to the company. The tablets come in three different strengths. Cidmus recorded sales of Rs 136.4 crore in India for the most recent twelve months ending in February 2022, according to IQVIA MAT data.

Dr Reddy's plans to use its large customer base to engage with healthcare professionals, as well as expand the product's reach beyond metros into tier-I and tier-II markets in India, through its strong marketing and distribution network, to provide more access to patients in need, according to the company.

Cidmus' acquisition is yet another endeavour by a large pharmaceutical company to provide access to well-known brands for healthcare professionals and patients. Given the high frequency of cardiovascular disorders in India, this acquisition will enable Dr Reddy's to provide patients with a trusted portfolio of medicines, according to the company. The medication will complement the company's existing cardiovascular portfolio, which includes leading brands like Stamlo, Stamlo Beta, Reclide-XR, and… Continue Reading...

Tagged: Novartis   Dr Reddy  
Disclaimer: SoOLEGAL in Media collaboration with Lawstreet Journal. SoOLEGAL take no responsbility for the content provided by Lawstreet Journal. For any discrepancies Contact Lawstreet Journal.
Did you find this write up useful? YES 1 NO 0

C2RMTo Know More

Something Awesome Is In The Work









Sign-up and we will notify you of our launch.
We’ll also give some discount for your effort :)

* We won’t use your email for spam, just to notify you of our launch.

SAARTHTo Know More

Launching Soon : SAARTH, your complete client, case, practise & document management SAAS application with direct client chat feature.

If you want to know more give us a Call at :+91 98109 29455 or Mail